The evolution towards ambulatory and day‐case management of febrile neutropenia
- 31 August 2006
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 135 (1), 3-16
- https://doi.org/10.1111/j.1365-2141.2006.06253.x
Abstract
Febrile neutropenia (FN) is only second to chemotherapy administration as a cause of hospital admission during treatment for cancer. As FN may signify serious or life-threatening infection, management protocols have focussed on trying to prevent adverse outcomes in these patients. However, it is now possible to identify a subset of patients with FN at low risk of life-threatening complications in whom duration of hospitalisation and intensity of therapy can be reduced safely. This review discusses how the management of FN has evolved to enable patients identified as low risk to be treated on specific low risk management strategies, with an emphasis on some of the practical considerations for the implementation of such strategies.Keywords
This publication has 90 references indexed in Scilit:
- Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive proteinEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trialsJournal of Antimicrobial Chemotherapy, 2004
- Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index scoreSupportive Care in Cancer, 2004
- Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant diseaseCancer, 2003
- Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategiesCritical Reviews in Oncology/Hematology, 2002
- Outpatient parenteral antibiotic therapy in patients with haematological malignanciesSupportive Care in Cancer, 2001
- Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropeniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremiaThe Journal of Pediatrics, 1996
- Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic conditionThe Journal of Pediatrics, 1994
- Single Daily Dose Ceftriaxone Plus Amikacin Treatment of Febrile Episodes in Neutropenic Patients Attending Day Hospital for Hematologic MalignanciesOncology, 1992